Human Epidermal Growth Factor Receptor 2 (HER2) mutations are present in about 2% of lung adenocarcinomas and induce the constitutive activation of HER2 protein, leading to the activation of EGFR through heterodimerization [31]. The gene discussed is ERBB2; the disease is lung adenocarcinoma.